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BY JON STONE, INGRID HOERITZAUER, 
AND MARK HALLETT
F unctional neurological disorders, also known as psychogenic, conversion, or non-organic disorders, account 
for at least one in six new attendances to 
neurology clinics1. Traditionally ignored 
in neurology research and training, this 
trend has been slowly reversing itself  
over the last decade. 
There have been significant advances 
in classification, phenotyping, under-
standing of  etiology, and mechanism as 
well as new and encouraging evidence 
for treatment. Functional neurological 
symptom disorder, the alternative name 
for conversion disorder in DSM-5, 
witnessed two important changes in diag-
nostic emphasis from DSM-IV. A psycho-
logical stressor is no longer required 
to make the diagnosis. It is now clear 
that not all patients have them. More 
importantly, the criteria emphasize that 
this is not a diagnosis of  exclusion. The 
patient must have positive physical signs 
of  a functional disorder, such as Hoover’s 
sign of  functional leg weakness, a tremor 
entrainment sign, or positive features of  
a dissociative/psychogenic (non-epileptic) 
seizure. 
Neurologists have long used such 
signs to make the diagnosis, but now 
there is a range of  evidence to support 
their use. Inclusion in the neurology 
section of  the forthcoming ICD-11 also 
will reflect these disorders’ status at 
the interface between neurology and 
psychiatry2.
New ideas and studies have 
introduced the importance of  separating 
etiology (the wide range of  biological 
and psychosocial factors that may make 
someone vulnerable to a functional 
disorder) from mechanism. For instance, 
how does the nervous system go wrong 
to lead to the symptom of  a weak leg or 
a blackout? Clinically, we recognize that 
patients’ symptoms are characterized 
by movements that look voluntary, but 
experienced by the patients as invol-
untary. Functional MRI (fMRI) studies 
BY RAAD SHAKIR, MD
I f someone anywhere in the world had a stroke or a TIA in the last 60 years, the World Health Organization (WHO) 
coding system placed the event under either 
vascular diseases or episodic symptoms, not 
in the appropriate central nervous system 
chapter of  ICD-10. This situation started 
with ICD-7 in 1955 
and has continued 
since. It skews all 
statistics of  neurolog-
ical diseases produced 
by the WHO. ICD-10 
has been in use 
since 1990, and a 
total revamp is long 
overdue. The infor-
mation is not only 
stale and old, but incorrect. Codes such as 
“slow virus infection” for prion diseases are 
expected to be used in the 21st century?
The WHO Department of  Mental 
Health and Substance Abuse, where 
neurology sits, commissioned a Neurosci-
ences Topic Advisory Group (Neurology 
TAG) in 2009. I have had the privilege 
of  chairing the TAG, which expanded 
to involve specialists from all neurosci-
ence specialties. The tasks were huge and 
detailed. The aim was to produce ICD-11, 
which will both serve the needs of  the non-
specialists as well as those working in highly 
developed institutions.
Perhaps the most important ICD-10 
anomaly the TAG faced was the situation of  
cerebrovascular diseases (CVDs) and their 
future placement in ICD-11. Attempting 
change of  the basic architecture of  ICD-10 
required a major case to be made on the 
reasoning and practicality of  changing an 
existing status. CVDs fell under Circulation 
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Stroke: Back to Where It Belongs
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Brain imaging studies capture the evolution of acute ischemic stroke in two patients.
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suggest an abnormal network, including 
prominently the temporoparietal junc-
tion, which may be associated with 
aberrant motor planning, and a reduction 
in the sense of  “agency” for movement. 
These are core to the experience of  
patients3,4. (See Figure 1.) fMRI also has 
shown abnormal connectivity between 
emotional centers, such as the amygdala 
and the premotor areas in patients with 
functional disorders, not seen in healthy 
controls5. 
Symptom Generation
Studies in motor and seizure symptoms 
converge on the importance of  an initial 
triggering event, such as physical injury, 
panic attack, or fainting, in shaping 
symptoms. Models of  symptom genera-
tion emphasize the importance of  a state 
of  abnormal-self-directed attention in 
which a top-down process driven in part 
by these triggering events and their effect 
on patient’s expectations can fundamen-
tally and persistently alter sensation and 
action regardless of  the patient’s current 
emotional state6. Taken together, recent 
studies suggest a disorder of  abnormal 
integration of  agency and sensorimo-
tor brain function that cannot be neatly 
pigeonholed as either purely neurological 
or psychological. 
Neurologists have often expressed 
pessimism about treatment outcomes 
for functional disorders. Some solutions 
are, however, becoming clearer. There 
is general agreement that successful 
communication of  the diagnosis is an 
essential platform to allow further treat-
ment to succeed. Bewildered or angry 
patients who feel they are being accused 
of  feigning symptoms are probably 
not going to do as well as those whose 
neurologists have helped them to see 
that they have a common, genuine, and 
potentially reversible condition1. 
Online resources that have been made 
available by health professionals include 
www.neurosymptoms.org. Resources 
for patients include www.fndhope.org 
and www.fndaction.org.uk. 
Randomized Controlled Trials
For patients with motor symptoms, 
physical therapy specifically designed for 
the unique nature of  functional disorders 
has now been demonstrated to be an 
effective treatment in two randomized 
controlled trials (RCTs). 
An RCT of  a five-day physiotherapy 
program in 60 patients with functional 
motor disorders and a mean duration 
of  symptoms of  5.8 years showed an 
improvement at six months in 72 percent 
of  the intervention group compared 
to only 18 percent of  controls under-
going a similar quantity of  generic 
physiotherapy7. 
Another trial of  in-patient treatment, 
also of  60 patients, showed an increase of  
seven points on a 15-point mobility scale. 
Effects were sustained at one year even 
though patients had been treated nine 
months after symptom onset8.
Two RCTs of  psychological therapy 
for dissociative (non-epileptic) seizures 
also have been encouraging, and a larger 
multicenter study is under way in the 
U.K. 9,10,11. Cognitive behavioral therapy 
can focus on identifying the warning 
symptoms that commonly herald a 
seizure (but are often unreported by 
patients), tackling avoidance, and dealing 
with thoughts that may influence seizure 
control, such as mood or self-esteem. 
Reduction in seizure frequency was 
maintained at a six-month follow-up 
despite a six-year duration of  events. 
Neurologists often find the diagnosis 
and treatment of  functional disorders a 
challenging and negative experience,  
one that is often mirrored and ampli-
fied by the patient’s unhappiness. The 
message from the new wave of  research 
on this topic is, “It doesn’t have to be this 
way.” 
As neurologists, we can turn those 
negatives into a positive. We can learn 
to make diagnoses, as we do for other 
conditions, based on positive clinical 
features, not normal investigations; 
appreciate that these disorders need an 
understanding of  the brain as well as the 
mind; and recognize that evidence-based 
psychological and physical treatment 
in the context of  a transparent and 
supportive initial neurological encounter 
can be surprisingly effective.
Upcoming Conference
If  this update has whet your appetite, 
you are invited to the third International 
Conference on Functional (Psychogenic) 
Neurological Disorders that will take 
place Sept. 6-8, in Edinburgh, Scotland. 
(www.fnd2017.org). 
This unique event, based on a recent 
51-chapter volume of  the Handbook of  
Clinical Neurology series12, and supported 
Figure 1. Resting state fMRI in 35 patients 
with functional movement disorder (FMD) 
compared to 35 controls. FMD patients had 
decreased functional connectivity between 
the right temporoparietal junction and 
bilateral sensorimotor regions, suggesting 
impaired motor feed-forward and sensory 
feedback signaling to this integrative region 
involved in “agency.” Threshold set at 
p<0.02; cluster size 28 voxels. Z score of  
>2.33 is equivalent to p<0.01. Reproduced 
with permission from reference 3. 
see FUNCTIONAL DISORDERS, page 3
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BY STEVEN L. LEWIS, MD, EDITOR,  
AND WALTER STRUHAL, MD, CO-EDITOR 
W e are pleased to introduce the May/June 2017 issue of World Neurology. The issue begins 
with the important news from WFN 
President Raad Shakir (see page 1), who 
reports on the momentous and exciting 
decision by the World Health Organiza-
tion to classify Stroke under the Central 
Nervous System chapter of the Interna-
tional Classification of Diseases (ICD-
11). On the topic of stroke, Dr. Wolfgang 
Grisold, secretary-general of the WFN, 
and Dr. Mohammed Wasay, remind us 
that the topic of World Brain Day 2017 
is devoted to stroke awareness, preven-
tion, and management. Dr. William 
(Bill) Carroll, first vice president of the 
WFN, and the convener of the Global 
Neurology Network, provides the 
background and analysis underlying 
the need for a global neurology alliance 
to address the global burden of neuro-
logical disease.
Dr. Grisold and Riadh Goulder, MD, 
provide their report on the recent and 
highly successful first African Academy 
of Neurology (AFAN) Conference & 
15th Pan Arab Union of Neurological 
Societies (PAUNS) meeting that was  
just held in March in Yasmine-
Hammamet, Tunisia. Marina Alpaidze, 
MD, PhD, and Alexander Razumovsky, 
PhD, FAHA, report on the third WFN 
neurosonology teaching course that 
took place in October 2016 in Tbilisi, 
Georgia.
Dr. Mohammad Bassam Hayek, a 
neurologist in Aleppo, Syria, and the 
vice president of the Syrian Society 
for Neuroscience, provides us with an 
important on-the-scene update on the 
recent and current state of neurology 
and neurological care in Syria. 
Giordani Rodrigues dos Passos, MD, 
reports on his recent eye-opening and 
successful participation in the Cana-
dian/WFN Department Visit Program, 
where he visited the Montreal Neuro-
logical Institute in March. In another 
successful report from the Rabat/WFN 
Teaching Visit Program, Dr. Boubacar 
Maiga reports on his experience from 
his one-year fellowship in clinical neuro-
physiology at University Mohamed-V in 
Rabat, Morocco.
Drs. Jon Stone, Ingrid Hoeritzauer, 
and Mark Hallett provide us with a brief, 
up-to-date, and authoritative review 
of the current thinking with regard 
to the classification, pathophysiology, 
diagnosis, and management of func-
tional neurologic disorders, including 
an invitation to learn and share more at 
the third International Conference on 
Functional Neurological Disorders to be 
held in September in Edinburgh. In this 
issue’s history column, Dr. M.J. Eadie 
provides us with a historical view of 
the emergence of clinical neurology in 
Australia, and the key neurologic figures 
who contributed to this rich history.
You also will find the nice reports 
and descriptions from each of the 
four candidate city venues for World 
Congress of Neurology 2021. Each city 
also will be presenting (for voting by  
the Council of Delegates) at the 
upcoming World Congress of Neurology 
in Kyoto, Japan. Also in this issue is 
the announcement from the WFN 
Nominating Committee with regard to 
the listing of the candidates for WFN 
leadership and trustee positions to be 
voted on by the Council of Delegates in 
Kyoto. (Note: The statements from the 
candidates for president and vice presi-
dent will appear in the upcoming [ July/
August] issue.)
Tissa Wijeratne, MD, provides an 
intriguing biographical sketch of his 
pathway and journey from the “ jungle” 
of Sri Lanka to becoming a neurologist. 
Finally, Dr. Grisold and Robert Schmid-
hammer, MD, provide a heartfelt obit-
uary for Dr. Hanno Millesi, a renowned 
peripheral nerve surgeon.
We sincerely hope that you will enjoy 
the many and varied contributions in 
this issue for and about neurology and 
neurologists around the globe. •
WORLD FEDERATION OF NEUROLOGY 
Editors-in-Chief 
Steven L. Lewis (Editor)
Walter Struhal (Co-editor)
WFN London Office
Chester House 
Fulham Green
81-83 Fulham High Street 
London  SW6 3JA 
United Kingdom
Tel.: +44 (0)20 3542 1657/1658
Fax: +44 (0)20 3 542 1301
info@wfneurology.org
WFN OFFICERS 
President Raad Shakir (United Kingdom)
First Vice President William Carroll (Australia)
Secretary General Wolfgang Grisold (Austria)
Treasurer Richard Stark (Australia)
ELECTED TRUSTEES
Morris Freedman (Canada)
Riadh Gouider (Tunisia)
Steven L. Lewis (USA)
CO-OPTED TRUSTEES
Gallo Diop (Senegal)
REGIONAL DIRECTORS
Saeed Bohlega (Pan-Arab)
Terrence L. Cascino (North America)
Günther Deuschl (Europe)
Marco Tulio Medina (Latin America)
Man Mohan Mehndiratta (Asian-Oceania)
Mansour Ndiaye (Pan-Africa)
EDITOR OF THE JOURNAL  
OF THE NEUROLOGICAL SCIENCES
John England (USA) 
WORLD NEUROLOGY, an official publication of 
the World Federation of Neurology, provides reports 
from the leadership of the WFN, its member societ-
ies, neurologists around the globe and news from 
the cutting-edge of clinical neurology. Content for 
World Neurology is provided by the World Federa-
tion of Neurology and Ascend Integrated Media.
Disclaimer: The ideas and opinions expressed in 
World Neurology do not necessarily reflect those of 
the World Federation of Neurology or the publisher. 
The World Federation of Neurology and Ascend 
Integrated Media will not assume responsibility for 
damages, loss or claims of any kind arising from 
or related to the information contained in this 
publication, including any claims related to the 
products, drugs or services mentioned herein.
Editorial Correspondence: Send editorial  
correspondence to World Neurology, Dr. Lewis  
at steven_lewis@rush.edu or Dr. Struhal  
at walter.struhal@akh.linz.at.
World Neurology, ISSN: 0899-9465, is published  
bimonthly by Ascend Integrated Media  
6710 W. 121st St., Suite 100 
Overland Park, KS, 66209  
Phone +1-913-344-1300 
Fax: +1-913-344-1497
©2017 World Federation of Neurology
PUBLISHING PARTNER
Ascend Integrated Media
President and CEO
Barbara Kay
Vice President of Content
Rhonda Wickham
Vice President of eMedia
Scott Rarden
Vice President of Sales
Donna Sanford
Project Manager
Amanda Nevala
Art Director
Brianna Vaughn
Editorial Offices
6710 W. 121st St., Suite 100
Overland Park, KS 66209
+1-913-469-1110
F R O M  T H E  E D I T O R S
STEVEN L. 
LEWIS, MD
WALTER 
STRUHAL, MD
CANDIDATE NOMINEES 
ANNOUNCED
The WFN Nominating Committee 
announces the candidates for the 
following positions. The Council 
of Delegates will vote during the 
WFN elections at the upcoming 
World Congress of Neurology in 
Kyoto, Japan. 
President
• Professor William M. Carroll,  
Australia
• Professor Wolfgang Grisold,  
Austria
Vice President
• Professor Ryuji Kaji, Japan
• Professor Renato J. Verdugo, 
Chile
Elected Trustee
• Professor Riadh Gouider,  
Tunisia
• Professor Man Mohan  
Mehndiratta, India
by the Movement Disorders Society, will 
bring together neurologists, psychiatrists, 
psychologists, physiotherapists, and other 
health professionals to discuss semiology, 
mechanism, etiology, and treatment of  
the whole range of  functional disorders 
seen in neurological practice over a 
three-day program. 
Speakers will include Joe Jankovic, 
Tony Lang, Chris Goetz, Tony David, 
Markus Reuber, Valerie Voon, Marina 
Konig-Tijssen, Curt LaFrance, Mark 
Edwards, and Sir Simon Wessely. •
Jon Stone and Ingrid Hoeritzauer are from the Center 
for Clinical Brain Sciences at the University of Edin-
burgh in Edinburgh, Scotland. Mark Hallett is from 
the Human Motor Control Section of the National 
Institutes of Health in Bethesda, Maryland. 
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The Need for a Global Neurology Alliance
Developing progress, while exciting, is creating problems that need to be addressed
BY W. (BILL) M. CARROLL, MB, BS, MD, FRACP, 
FRCP(E)
R ecently, there has been an explosion of  health awareness recognized by individuals, nations, and the global 
community. The decade of  the brain was 
followed by the human genome project, 
accompanied by the near eradication of  
malaria and polio. Yet, we now stand at 
the threshold of  even more rapid advances 
on many fronts. 
3-D printing of  
the human heart is 
being used in plan-
ning cardiac surgery. 
Next-genome 
sequencing is 
revolutionizing old 
concepts of  disease. 
Gene therapy 
shows success in 
some inherited 
neuropathies (spinal 
muscular atrophy) 
and myopathies (Duchenne muscular 
dystrophy). Precision medicine is no longer 
an aspiration in some diseases and coun-
tries, and the ability to use publicly acces-
sible data via expanding cloud technologies 
is yielding unexpected information and the 
repurposing of  medications. Conversely, 
the cost of  drug development, especially 
in bringing them to market, is becoming 
prohibitive, exacerbating the accessibility 
of  therapies in many countries. 
For the thoughtful and the less fortu-
nate, it is obvious that the developing 
progress, while exciting and to be cele-
brated, is creating problems that need to 
be addressed. The increasing burden of  
non-communicable diseases (NCD) adds up 
to what can only be viewed as a potential 
tsunami for the economies of  the world. 
These NCDs include mental (neurological) 
and substance-abuse disorders; muscu-
loskeletal disorders; neurodegenerative 
conditions such as dementia, stroke and 
Parkinson’s disease; poor lifestyle choices 
in diet and exercise; and the effects of  
unhealthy environments1 together with the 
changing demographic of  aging popula-
tions in so-called developed countries. 
Those people and countries least  
able to afford the advances and/or mobi-
lize services to adjust to them will see a 
widening gap, not only in these areas of  
disease but also in their ability  
to respond to the periodic recrudescence 
of  infectious disease. This was seen with 
the outbreaks of  Ebola, MERS, SARS, 
and, most recently, the Zika emergency. 
It is not by chance that the recent 
waves of  mass migration have occurred 
as much because people seek better 
lifestyles (and health services) as fleeing 
armed conflict.
It is in this environment that those in 
the neurological fraternity need to mobi-
lize and prepare measures at a number of  
levels that will mitigate the consequences 
of  these changes. To begin, we must look 
at the magnitude of  the problems facing 
us. Then, we will evaluate the resources 
we have available. Finally, we will view 
three illustrations of  how those resources 
can be optimized to provide the organi-
zational readiness for rapid and effective 
action as well as long-term planning on a 
national, regional, and global scale. 
The Problem
The global burden of  neurological disease 
figures as a relatively small fraction of  the 
global burden of  all disease (GBD) for a 
range of  reasons2. Although not included 
in the WHO 2014 global status report on 
NCDs3, stroke and dementia are of  major 
concern to clinicians and national health 
systems.
The annual stroke toll is approximately 
15 million, with one-third being fatal and 
another third permanently disabling. 
Indeed, stroke mortality is double that 
of  HIV/AIDS, malaria, and tuberculosis 
combined, emphasizing the rising burden 
of  brain NCDs. With rates of  dementia 
estimated to triple from 47.5 million to 115 
million worldwide by 20504, it is clear that 
the world faces a rising impost on resources. 
Currently, the total burden of  mental, 
neurological, and substance abuse 
(MNS) is now reckoned to be 258 million 
disability-adjusted life years — a measure 
of  overall disease burden expressed 
as the number of  years lost due to ill 
health, disability, or early death. That is 
up from 182 million in 1990, which has 
been equated to a $8.5 trillion (U.S.) loss 
of  economic value now, and which will 
increase again by a factor of  two by 20305. 
With the addition of  other NCDs to 
stroke and dementia, it is clear that the 
world neurological fraternity must act 
in concert and alert governments. Those 
other NCDs include age-related Parkin-
son’s disease and other chronic neurode-
generative disease, perinatal injury largely 
due to asphyxia, childhood developmental 
and degenerative disease, schizophrenia, 
high levels of  traumatic brain disease, all 
causes of  epilepsy, substance and alcohol 
abuse, and rising neuroinflammatory 
disease of  the brain and spinal cord.
While world neurological expertise has 
been steadily advancing partly in parallel 
with the recognition of  the increasing 
challenges on the horizon and partly with 
the advances in medical science, it is far 
from equitably distributed. When the 
widening gap between well-developed 
countries with comprehensive health care 
and those less developed populations and 
health care systems is appreciated, the 
likelihood for an emergency is evident6.
Resources
There are a number of  valuable resources 
available. These include measures of  the 
GBD and specific problem areas, such as 
the NCDs, BNCDs, and MNSs, as well as 
WHO monitoring for more acute chal-
lenges to health through national health 
departments and WHO’s regional struc-
tural organization. (The WHO regional 
organization mirrors approximately that 
of  the WFN). The periodic assessments 
of  the GBD by the WHO and the Atlas of  
Neurology (a joint WHO-WFN project) 
provide the broad sweep, big picture view 
of  resources and needs.
The WFN itself  plays an important and 
growing role in the equalization of  access 
to neurological care both through regional 
organization support and neurological 
education. The establishment of  the African 
Academy of  Neurology (AFAN) and its first 
meeting in Tunis this year are illustrative. 
It joins the expanding roles of  other WFN 
regional organizations, including the Pan 
American Federation of  Neurological Soci-
eties (PAFNS), the Australasian and Ocea-
nian Association of  Neurology (AOAN), 
the Pan Arab Union of  Neurological 
Societies (PAUNS), the American Academy 
of  Neurology (AAN), and the European 
Academy of  Neurology (EAN). 
Neurological training, the improve-
ment in access to neurological care, and 
an increasing awareness of  the importance 
of  brain health in the general population 
are furthered by World Brain Day (WBD)7 
and the biennial World Congress of  
Neurology (WCN). The WFN, in partner-
ship with AFAN, has followed the World 
Federation of  Neurosurgical Societies 
(WFNS) program to train young African 
specialists. The WFN plans to have four 
regional training centers in Africa — two 
each for the Francophone and Anglo-
phone regions. Additional emphasis of  
World Brain Day 2017
Stroke is a brain attack: Prevent it and treat it
BY MOHAMMED WASAY, MD, AND  
WOLFGANG GRISOLD, MD
T his year’s World Brain Day commemorates the foundation of  the WFN. The prior World Brain 
Day topics were aimed at epilepsy and 
dementia, and now it is aimed at stroke. 
We are partnering this time with the 
World Stroke Organization (WSO), 
which puts great global effort into the 
prevention and treatment of  stroke.
The topics of  this World Brain Day 
should be the awareness of  stroke, the 
symptoms, the prevention, and the 
new evidence for optimized treatment. 
Neurorehabilitation is increasingly 
becoming important.
World Brain Day is supported by the 
Public Awareness committee jointly with 
the WSO to make this day a success. 
As in the previous World Brain Days, 
a special logo will be produced, as well 
as material for local use, which can be 
used with the regional societies. Prior 
to World Brain Day, a template for press 
mailings will be distributed to help the 
local organizations. Closer to World 
Brain Day, a webinar will be accessible 
and, with invited participants from the 
press, will spread the news.
Despite these activities and help, the 
success of  World Brain Day depends on 
your local activities. Please make the 
World Brain Day your own, use all of  the 
material we provide, and ask for more 
if  needed. Experience has shown that 
this international day has created much 
press attention, but local activities and 
information make the difference.
Please involve patients, caregivers, the 
public, and interested patient groups who 
will be interested in this topic. Stroke care 
faces many global inequalities, in regard 
to infrastructure, care, and support!
Needless to say, we are eagerly 
awaiting your reports of  your local 
events, so we can publish them in World 
Neurology. Also, please post your activi-
ties on social media. •
see ALLIANCE, page 5
W. (BILL) M. 
CARROLL, MB, 
BS, MD, FRACP, 
FRCP(E)
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WFN involvement at a global level was 
given by WFN President Raad Shakir as 
chair of  the Neurosciences Topic Advisory 
Group for the WHO-sponsored Interna-
tional Classification of  Disease (ICD-11), 
due for release in 2018. 
More generally, other areas are devel-
oping, which will enhance the ability to 
respond to challenges. Increasingly rapid 
communication through electronic media, 
including social media, draws attention 
to emerging problems. The maturation 
and expanding expertise of  neurological 
subspecialties and their involvement 
in wider educational activities (e.g. the 
International League Against Epilepsy, 
the World Stroke Organization, and the 
Movement Disorders Society) as well as 
the added interest of  the larger regional 
neurological organizations, such as the 
AAN and EAN, provide a rich resource of  
intellectual and monetary capital. 
Over the last few years, the WFN has 
provided a focal point for those involved 
in the medical care of  neurological disease 
through two similar, though importantly 
different, groups. The first is the World 
Brain Alliance (WBA). Originally chaired 
by Vladimir Hachinski, MD, when he 
was WFN president, it is now chaired by 
Dr. Shakir. The WBA members include, 
in addition to the WFN, global organiza-
tions that usually do not include neurolo-
gists, such as the WFNS, the International 
Brain Research Organization (IBRO), the 
World Psychiatric Association (WPA), the 
International Child Neurology Associa-
tion (ICNA), and the World Federation of  
Neurorehabilitation (WFNR). The second 
group is the Global Neurology Network 
(GNN) for which the WFN is the current 
convener and whose members mainly 
include neurological disease-specific organi-
zations from around the world. Many were 
originally part of  the WFN but have grown 
to be independent organizations. They 
include the World Stroke Organization 
(WSO), the International League Against 
Epilepsy (ILAE), the Multiple Sclerosis 
International Federation (MSIF), the Treat-
ment and Research in Multiple Sclerosis 
(TRIMS) Group, Alzheimer’s Disease 
International, the Movement Disorder 
Society, the International Headache Society, 
the International Society for Clinical 
Neurophysiology, the Peripheral Nerve 
Society, and the Tropical Disease Group. 
Closely associated with this category of  
disease-specific organizations are both 
large regional organizations supporting 
all neurological subspecialties, such as the 
AAN and the EAN, and the smaller WFN-
affiliated regional organizations, such as the 
AOAN, PAUNS, PAFNS, and AFAN. 
Together, these two groups create an 
impressive global alliance of  neurological 
expertise. It is an alliance appropriately 
suited to provide global disease-specific 
advice to international organizations, such 
as the WHO and the U.N., and to advocate 
with these organizations and national 
governments. It is an alliance worthy of  
the term Global Neurology Alliance.
Recent Examples of United Action 
The most critical function of  a global alli-
ance of  neurological organizations is the 
ability to formulate, organize, and execute 
rapid and effective policy or reaction. A pow-
erful advocacy initiative that can mobilize 
governments and NGOs is of  enormous 
value to those under threat, and it is the ra-
pidity of  communication and the common 
understanding of  the advocating group that 
empower these initiatives as a force for good. 
Underlying this ability are two 
fundamentals. The first is an intimate 
understanding by the subspecialty organi-
zation in the national, regional, and global 
spheres of  all matters affecting practitioners 
and patients. The second is the intercom-
munication among the various subspecialty 
organizations facilitated by the GNN. 
Regular meetings, updates on activities, and 
a common understanding of  the means to 
reach their constituencies contribute to the 
effectiveness of  the network.
Recent examples of  where this alli-
ance has been called to mobilize and has 
proven its worth are the 2015 Zika virus 
outbreak, the WHO initiative on NCDs, 
and the crisis over the WHO classifica-
tion of  stroke as a circulatory rather than 
neurological disease. 
The outbreak of  the arthropod-borne 
(Aedes aegypti) Flavivirus crisis, known 
as Zika virus, in April 2015 in Brazil, was 
designated by the WHO in February 2016 
as a public health emergency of  interna-
tional concern (PHEIC)8. 
Zika was first found in Uganda in 
1947, and the first outbreak of  disease 
occurred in Micronesia in 2007. The South 
American outbreak was much worse. The 
primary infection was often asymptomatic 
or relatively banal, comprising arthromy-
algia, a light rash, or a low-grade fever. 
The major secondary effects were of  brain 
neuronal migration injuries to the fetuses 
of  pregnant women manifesting often, but 
not solely, as microcephaly, and a postin-
fectious neuropathy resembling Guillain-
Barré syndrome. 
Given the unknowns with this outbreak 
The most critical function of  a global  
alliance of  neurological organizations is the 
ability to formulate, organize, and execute 
rapid and effective policy or reaction. 
ALLIANCE
continued from page 4
The State of Neurology in Aleppo
Patient treatment in war-torn Aleppo suffered, but is struggling to return to normalcy
BY DR. MOHAMMAD BASSAM HAYEK
A leppo, Syria, was subjected to a comprehensive war that directly affected all of  its humanitarian 
services. Before July 2012, the difficulties 
were limited, with most related to security 
and transport problems.
However, by the end of  July, the city 
had been torn into two large sections. 
With daily bombardments and clashes, 
the city’s population plummeted from 
4.5 million to 1.5 million. Coinciding 
with this, the city experienced a complete 
absence of  electricity, a severe decline in 
health services, and an insufficient number 
of  beds available for hospitalization of  
stroke patients in government hospitals.
The quality of  service provided by the 
private sector decreased. No MRI device 
was in service, either in the governmental 
or private sectors. Seventy percent of  the 
CT machines no longer worked. 
A number of  neurologists (about 12 
out of  30 doctors) left because of  the secu-
rity chaos. There were no neurologists in 
the area controlled by the armed people. 
Patients had to travel for several days to 
see a neurologist.
This was accompanied by the interrup-
tion of  the supply of  most neurological 
drugs from local markets, especially anti-
epileptics (valproate, carbamazepine, and 
phenytoin) and all antiparkinson drugs.
In addition to the unavailability of  the 
necessary anticoagulants for stroke, one 
of  the most important challenges was 
the loss of  records for the treatment of  
multiple sclerosis (MS). About 900 patients 
had been periodically reviewed for free 
medical service and treatment (interferon 
beta of  all kinds). Patients were dispersed, 
some migrated, and others had new 
attacks without finding the right medica-
tion (methylprednisolone) or the correct 
diagnosis.
All physiotherapy services disappeared. 
Although there were a number of  thera-
pists, the work was futile.
Due to the many injuries associated 
with shrapnel and peripheral nerve trauma, 
neurophysiologists for electromyogram 
and nerve conduction velocity tests were 
needed. There also was the occurrence of  a 
number of  cases of  flaccid paralysis, and it 
was difficult to find treatment.A hospital with 40 beds, built in 1943 and rehabilitated in 2014, has a physiotherapy and 
rehabilitation department with an EEG machine. see ALEPPO, page 7
A workshop about epilepsy was presented 
during a training course funded by the World 
Health Organization. 
see ALLIANCE, page 6
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BY ROBERT SCHMIDHAMMER, MD, AND  
WOLFGANG GRISOLD, MD, 
U niversity Professor Dr. Hanno Millesi, a doyen of  modern nerve surgery, died April 28, 2017, in 
Vienna, Austria. He was 90.
Dr. Millesi was born in Austria in 
1927. He finished his medical studies in 
Innsbruck in 1951, and started his career 
in surgery at the University of  Vienna. 
He was one of  the founders of  plastic 
and reconstructive surgery in Austria, and 
chaired the department at the University 
of  Vienna until his retirement in 1995. He 
has a long list of  international achieve-
ments, including being a member of  the 
Sunderland Society, the International 
Society for Reconstructive Microsurgery, 
and the World Society for Reconstructive 
Microsurgery. He has a long list of  publica-
tions and books, and was actively involved 
in peripheral nerve research until his death.
Dr. Millesi had an eminent interest in 
surgery of  the peripheral nerves, and was 
one of  the pioneers in using autologous 
nerve transplant, which revolutionized 
the concept of  nerve repair. He also 
developed the methodology of  microsur-
gical neurolysis, which aims to decom-
press nerve fascicles.
He remained active in the field of  
research until his death. In his last years, 
he was devoted to tissue and environment 
of  peripheral nerves, in particular nerve 
gliding. Increasingly, he incorporated the 
new imaging methods, in particular high-
resolution ultrasound, in his concepts.
Dr. Millesi was a dedicated physician, 
and was appreciated for his lexical knowl-
edge and his ability to consult and advise. 
He was tireless with regard to patient 
issues and any aspects of  peripheral nerve.
Dr. Millesi was not only an excellent 
surgeon and scientist, but he also was a 
good example of  collaboration between 
the fields of  neurology and plastic and 
reconstructive surgery. His concepts 
of  nerve surgery, re-innervation, and 
applied neuroplasticity taught neurology 
a lot. These concepts have advanced the 
knowledge of  nerve repair and recon-
struction from a static approach to a 
highly dynamic field. •
Robert Schmidhammer, MD, is a university professor 
at Millesi Center in Vienna. Wolfgang Grisold, MD, 
is WFN secretary general and a professor at Ludwig 
Boltzmann Institute for Experimental and Clinical 
Traumatology in Vienna.
I N  M E M O R I A M
Hanno Millesi 
March 24, 1927-April 28, 2017
Dr. Hanno Millesi
Original sketch of a complex reconstruction of the brachial plexus, by Dr. Millesi (approxi-
mately 2005). (PHR: Phrenic nerve; C5: nerve root with neuroma; ACC: Accessory nerve; PMA: 
pectoralis major muscle; FAP: Posterior fascicle, SPSC Suprascapular nerve, lines depict sural 
nerve grafts (transplants); MC musculocutaneous nerve; IC Intercostal nerves.)
and the urgency to gather information, a 
committee, headed by John England, MD, 
was constituted, assisting the global inves-
tigation of  the outbreak. The committee 
was supported by WFN resources through 
the regional organization in South 
America, the expertise within the organiza-
tion, and the rapidity with which the WFN 
could respond to assist. PHEIC status was 
ceased in November 2016.
The NCD initiative, launched in 
2011 by the WHO following the GBD 
report highlighting the impact of  NCDs9, 
concentrated on cardiovascular disease, 
cancer, diabetes, and respiratory disease. 
Omitted were major illnesses central to 
brain health, such as dementia and stroke. 
The omission was questioned by the 
global neurological fraternity. The WFN, 
through its role as WBA convener and led 
by Dr. Shakir, waged a campaign to have 
brain NCDs included in the initiative5. 
How did such a situation arise? It 
seems that because the WHO viewed 
stroke and dementia not to be brain 
diseases but rather as circulatory and 
mental disorders, respectively, they were 
not included as risks to brain health. 
There are historical reasons for this view, 
which were defended by the WHO, but 
ICD-11 brought this matter to a head. In 
doing so, it also provides an illustration of  
the value of  a global neurological alliance.
The ICD is revised every decade. 
ICD-10 was adopted in 1990, and in 2007 
the revision ICD-11 was commenced 
under the supervision of  the Revision 
Steering Group, which took advice from 
a number of  Topic Advisory Groups 
(TAGs). The ICD-11 Neurology TAG was 
constituted in 2011 under the leadership 
of  Dr. Shakir. Soon after this process 
commenced, stroke was apparently 
accepted as a disease of  the brain. When 
the beta version of  ICD-11 was published 
in 2016, the neurological and stroke frater-
nities were astounded to find that stroke 
had been changed to a circulatory disease. 
Clarity as to the reason stroke had 
been omitted from the NCD initiative had 
arrived. Stroke was not a brain disease. 
The decision galvanized the neurological 
and stroke communities. After consider-
able effort, it was determined that the 
powerful statistics group within the WHO 
had been at the forefront of  the opposition 
to the change initiated by the Neurology 
TAG. While the grounds for such opposi-
tion were reasonable and based on a desire 
to obtain the best longitudinal epidemio-
logical data, it effectively “hid” the impact 
of  stroke in the global community and 
paid little heed to the growing evidence 
of  the contribution of  cerebrovascular 
disease to dementia and NCDs in general. 
There followed initial correspondence 
to Lancet10 by the WFN and WSO, and the 
formation of  an ad hoc advisory group 
through the recruitment of  national 
departments of  health to voice opposi-
tion to the way stroke was handled by the 
WHO. A number of  important face-to-
face and telephone meetings took place, as 
well as a review of  the evidence, from the 
WSO perspective, of  why stroke should 
not be classified as only a circulatory 
disease. Through an innovation intro-
duced in ICD-11, multiple parenting was 
possible. This, together with the weight 
of  argument, has seen stroke, as of  April 
2017, classified as a cerebrovascular disease 
in the current beta version of  ICD-11—an 
event described by many as momentous. 
(See the President’s Column on page 1.) 
Conclusion
It is no accident that these external initia-
tives of  the WFN and partners have been 
successful. The ability to respond rapidly, to 
gather expertise, and to plan and imple-
ment the agreed approach, while maintain-
ing the flexibility to adapt to developments, 
are the prime reasons. That there has been 
an immediate sense of  shared purpose, and 
the acknowledgement that together we are 
better able to present the arguments firmly 
and authoritatively, has no doubt assisted. 
The foresight of  the originators of  these 
two groups has to be praised, as does the 
leadership of  the current WFN president 
and the members of  the WBA and GNN. 
With the world facing continuing uncer-
tainties, it is likely we shall see more reasons 
to be grateful for the contributions made 
by these groupings and to possibly have 
periodic joint meetings. In practice, these 
groups and their membership represent a 
truly global neurological alliance. •
ALLIANCE
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W. (Bill) M. Carroll, MB, BS, MD, FRACP, FRCP(E), 
is first vice president of the WFN and is the WFN 
convener for the Global Neurology Network.
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Turning the Corner
In January 2013, life was unbearable, and 
the city seemed to be gloomy without 
electricity or water, along with the decline 
of  all basic services.
By 2014, a road to the city opened, 
bringing supplies to the besieged popu-
lation. Small, private generators within 
neighborhoods delivered a limited 
supply of electricity. An MS committee 
was reorganized, and up to 365 patients 
were treated for free with beta inter-
feron, but the drugs were from generic 
companies.
Initially, one MRI was returned to 
service. In the private sector, three private 
devices are now operating. However, there 
are no devices in government hospitals 
that can be used for free. The average cost 
of  providing an MRI is $60. (The average 
monthly salary is $100.)
With the passing of  time, the service 
situation stabilized, and the security 
improved. The U.N.’s international 
organizations reached the city and helped 
improve the health system.
Since mid-2014, medicine has become 
available in an acceptable, but insuffi-
cient manner. Currently, most essential 
neurological drugs are available. The most 
important are antiepileptic drugs (carba-
mazepine, sodium valproate, lamotrigine, 
levetiracetam, and clonazepam), but the 
supply is unstable. There are still diffi-
culties in securing antiparkinson drugs, 
especially levodopa.
Continuing medical education and 
training have declined. The health sector 
has not prioritized the provision of  
services.
However, there have been improve-
ments since 2015. The road from Aleppo 
to Damascus has become safer. Scientific 
activity has slowly returned, but fear still 
prevails over some doctors.
Some of  the government hospitals are 
open, including a free neurology clinic at 
Ibn Khaldoun Hospital. There is free EEG 
service at three locations, and rehabilita-
tion at one of  the public hospitals is open 
to neurologic patients.
Training of  neurologists of  all ages 
is still an important need. This can be 
accomplished in seminars, scientific 
conferences, and specialized training 
programs. Neurological drugs through 
the World Health Organization are still 
needed. •
Dr. Mohammad Bassam Hayek is a neurologist in 
Aleppo, Syria. He is vice president of the Syrian 
Society of Neurosciences and general director of Ibn 
Khaldoun Hospital.
disease of  vessels. Statisticians, following the 
principle of  ascribing disorders to their basic 
etiology, followed this procedure, ignoring 
the fact that all of  the effects of  CVDs are 
neurological and that the initial interaction 
of  the neurovascular bundle is fundamental 
to the pathophysiology. Moreover, in 
ICD-10, other ischemic disorders affecting 
the eyes, bowels, and kidneys fall under the 
affected organs. Transient ischemic attacks 
were classified under episodic disorders 
separate from CVDs.
This situation is not only incorrect, but 
it has led to massive confusion of  reporting 
the fact that a leading cause of  death is not 
placed as a disease of  the brain. The first 
act the TAG performed was to contact and 
agree with our cardiology colleagues as 
cardiac events were lumped with CVDs, 
skewing their statistics as much as ours. 
They were asked to approve a total separa-
tion of  cardiac and brain diseases for the 
benefit of  both. This was successfully 
established with the Cardiology TAG in 
2011. It, of  course, remains that cardio-
genic causes of  CVDs are appropriately 
reported in both sections.
Where to Place CVDs?
The WHO statisticians were informed, 
and we had “initial acquiescence” until the 
middle of  2016, when a major statistician’s 
review of  ICD-11 was carried out by the 
WHO Department of  Informatics and 
Statistics. At that time, statistics advisers 
had second thoughts, which again placed 
all CVDs under the circulation section of  
the Joint Linearization for Mortality and 
Morbidity section of  ICD-11.  
This decision needed to be reversed, 
which required intensive lobbying to make 
the point that stroke is a brain disease. 
It has to be emphasized that the ICD is 
“owned” by the WHO statisticians, and 
our role as clinicians is advisory. 
Be that as it may, the TAG had to 
pursue this matter vigorously and provide 
the scientific reasoning for the change. 
WFN and the World Stroke Organiza-
tion (WSO) acted in a closely coordinated 
manner. Professor Bo Norrving, past presi-
dent of  the WSO, and I, the representatives 
of  the Neurology TAG, used all possible 
avenues to make the case for the WHO 
Department of  Informatics and Statistics. 
In addition to the production of  scientific 
evidence on the etiology of  stroke and 
the interactions between vessels and brain 
parenchyma, we needed to mobilize other 
players to reinforce the message of  the 
importance of  stroke being classified as a 
brain disease for resource allocation and 
training of  staff—medical, nursing, and 
others—to combat the scourge of  CVDs.
The issue is vital for the future of  
neurology, and The Lancet published two 
letters, one from us1, and the second a 
reply from the WHO Department of  
Informatics and Statistics2. We had put 
forward the argument for stroke moving to 
the central nervous system, while the ICD 
STROKE
continued from page 1
ALEPPO
continued from page 5
A hospital features an environment that helps stimulate recovery by emphasizing a water flat, 
gardens, and outdoor activities.
WFN NSRG Examines Clinical Applications
Faculty reviews the current state of neurosonology and specific clinical applications
BY MARINA ALPAIDZE, MD, PHD, AND  
ALEXANDER RAZUMOVSKY, PHD, FAHA
T he WFN Neurosonology Research Group (NSRG) is dedicated to the promotion of  science and research 
as well as education and training in the 
field of  ultrasonic techniques (carotid 
duplex and transcranial Doppler) and 
their clinical utilization. Therefore, 
international cooperation and the 
dissemination of  scientific informa-
tion within the field of  neurosciences 
and neurosonology is part of  the WFN 
NSRG activities.
On Oct. 22, 2016, the Georgian 
Chapter of  the WFN NSRG successfully 
conducted its third regional meeting in 
Tbilisi, Georgia. The meeting included 
participants from the neighboring 
country of  Azerbaijan. The one-day 
course was designed for individuals who 
are interested in performing and inter-
preting neurosonology studies.
The faculty discussed the current 
status of neurosonology and specific 
clinical applications, such as its clinical 
utilization on patients with dementia 
or an undetermined etiology of stroke. 
Relatively new aspects of neuro-
sonology applications were discussed 
for patients with neuromuscular disor-
ders and consequences of traumatic 
brain injury. Well-known neurologists 
and neurosonology experts deliv-
ered the lectures. These individuals 
included: 
• Marina Alpaidze, MD, of  Georgia, 
president of  the WFN NSRG Georgian 
Chapter and president of  Georgian 
Society of  Neurosonology and Cere-
bral Hemodynamics
• Eva Bartels, MD, PhD, of  Germany, 
vice chair for International Certification 
in Neurosonology
• Natan Bornstein, MD, PhD, of  Israel, 
vice president of  the World Stroke 
Organization and president of  the 
European Society of  Neurosonology 
and Cerebral Hemodynamics
• Aleksandr Dzhanashvili, MD, PhD, of  
the United States
• Tamar Janelidze, MD, PhD, of  Georgia
• Alexander Razumovsky, PhD, FAHA, 
of  the United States, secretary of  the 
WFN NSRG
• Ekaterina Titianova, MD, PhD, DSc, of  
Bulgaria, president of  Bulgarian Society 
of  Neurosonology and Cerebral Hemo-
dynamics
This third Georgian meeting was 
guided and directed under the auspices 
of  the NSRG of  the WFN and accred-
ited by the Tbilisi Medical University 
Continuing Medical Education (CME) 
Board for 10 CME hours. •
Participants at the third regional WFN NSRG meeting. (From left) Aleksandr Dzhanashvili, 
MD, PhD; Eva Bartels, MD, PhD; Ekaterina Titianova, MD, PhD, DSc; Natan Bornstein, MD, 
PhD; Alexander Razumovsky, PhD, FAHA; and Marina Alpaidze, MD.
see STROKE, page 8
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From Brazil to Montreal
WFN and the Canadian Neurological Society provide an observer learning opportunity at MNI 
BY GIORDANI RODRIGUES DOS PASSOS, MD
O ne month after completing my neurology residency in Brazil, I had the opportunity in March to 
participate in the Canadian Department 
Visit Program, during which I served as 
an observer at the Montreal Neurological 
Institute (MNI).
The administrative staffs of  the WFN 
and the MNI were excellent, both before 
and during my stay in Montreal. My 
schedule was arranged by Dr. Anne-
Louise Lafontaine, who made sure to take 
my main interests into account. 
My activities included:
• Clinics of  multiple sclerosis (MS), amyo-
trophic lateral sclerosis, neuromuscular 
disorders, and movement disorders at 
the Montreal Neurological Hospital 
(MNH) for three weeks
• Neurology wards and consultation at the 
Montreal General Hospital (MGH) for 
one week
• Weekly grand rounds and teaching 
sessions at both the MNH and the MGH
• Weekly meetings with the PET team at 
both the Brain Imaging Center/MNH 
and the Douglas Institute
• Meetings with professors and PhD 
students to discuss specific areas of  
interest
My main interest is MS, which is 
roughly 10 times more prevalent in 
Canada than it is in Brazil. From a clinical 
perspective, this observership was remark-
able because I saw several dozen MS 
patients, covering a wide range of  clinical 
aspects and treatment strategies. 
A number of  elements stood out for 
me relating to the functioning of  the MNI 
and the health care system in Canada. 
They included: 
• Health care and research are closely 
integrated with mutual benefits.
• The MNI is remarkably able to commu-
nicate its actions and achievements to 
the scientific community as well as the 
patients and society as a whole. This 
increases its ability to raise additional 
funds for research.
• Multidisciplinary teams at the clinics 
and in the wards improve significantly 
both the neurologists’ work and patient 
outcomes.
• Canadian neurology residents receive 
more in-depth training on neuro-
anatomy, pathophysiology, and semi-
ology than most of  their Brazilian 
counterparts.
Many of  these elements could be 
implemented in my workplace, an 
800-bed university hospital in southern 
Brazil. What I learned at the MNI will 
improve my practice as a neurologist and 
researcher in the coming years. It also will 
serve as a lesson when I have opportuni-
ties to participate in my hospital’s institu-
tional decisions. 
A minor drawback of  my observership 
was the March break, which took place 
during my first couple of  weeks there. 
During this time,  some of  the clinic’s 
work was suspended, and some of  the 
attending neurologists were away from 
the hospital. Even though I was able to 
find alternative clinical or academic activi-
ties to fill my schedule, I suggest the next 
observers be advised of  the March break 
and encouraged to choose another month 
for their MNI visit. 
Overall, this was an inspiring, career-
changing experience. I recommend the 
Canadian Department Visit Program for 
other young neurologists. I congratulate 
the WFN, the Canadian Neurological 
Society, and the MNI for fostering educa-
tion in neurology, and I am grateful for 
this opportunity. •
Giordani Rodrigues dos Passos, MD, works in the 
Department of Neurology at São Lucas Hospital in 
Porto Alegre, Brazil.
C A N A D I A N  D E P A R T M E N T  V I S I T  P R O G R A M
classification team put forth its reasoning, 
quoting continuity and the fact that CVDs 
were placed in ICD-7 in 1955.
This meant going to governments, as 
they are the ultimate power in the WHO 
structure. We are most grateful for the 
support, such as a most powerful letter from 
Veronica Skvortsova, the minister of  Health 
of  the Russian Federation, addressed to the 
WHO director general. Dr. Skvortsova is 
herself  a neurologist and therefore is fully 
aware of  this anomaly in ICD-10. We also 
are most indebted to the health ministries of  
Austria and New Zealand for their support. 
We were hugely supported by patient 
organizations that wrote to the WHO and to 
neurologists from across the world for their 
support. Following all of  this effort, a request 
came from the ICD classification team asking 
us to have another face-to-face meeting. This 
was conducted Dec. 21, 2016, in Geneva. 
The daylong meeting was most interesting as 
it started with the assertion of  the statisti-
cians on the importance of  continuity and 
stability of  statistics over decades. This is 
something crucial to us all. However, expla-
nations were provided with regard to the 
need for radical change and why it is crucial 
to rectify a previous anomaly. The WHO 
technical department where neurology sits 
was represented by Dr. Tarun Dua, who 
made the case for the need to place CVDs 
under the nervous system diseases chapter 
of  the ICD-11. The Neurology TAG was 
represented by Dr. Norrving and me. The 
meeting ended without an immediate 
outcome. We did not know the meeting’s 
conclusions for more than three months. The 
WHO ICD team had to clear its decisions 
with its statistics consultants from around 
the world. This is perfectly understandable as 
many computer systems have to be retuned, 
and this will need time and finance. 
Two further medical statistics meet-
ings took place. Finally, on March 31, I 
was informed by email: “The grouping 
‘Cerebrovascular Diseases’ has moved into 
‘Diseases of  the Nervous System.’” This is 
a culmination of  eight years of  work and is 
the most logical outcome for our endeavors. 
Now the world of  neurology is correctly 
represented. This is immediately reflected in 
the soon-to-be-published “Global Burden of  
Disease” paper, where in 2015 “neurological 
disorders rank as the leading cause group of  
DALYs (disability-adjusted life years) and the 
second-leading cause of  death in the world.” 
This means that resources will be appro-
priately allocated not only for CVDs but all 
neurological disorders. The WHO decision 
was truly momentous, and for that we are 
grateful. Stroke is back where it belongs. •
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Giordani Rodrigues dos Passos, observer (left), Mrs. Vanessa Spyropoulos, clinical nurse spe-
cialist in the MS program, and Dr. Yves Lapierre, director of the MNH Multiple Sclerosis Clinic.
Dr. Anne-Louise Lafontaine (center), chief of the Department of Neurology of the McGill Uni-
versity Health Center, and Giordani Rodrigues dos Passos (third from the right), observer, with 
neurology residents and medical students during rounds at the Montreal General Hospital.
Dr. Jack Antel (left), professor at McGill 
University and president of the Americas 
Committee for Treatment and Research in 
Multiple Sclerosis, and Giordani Rodrigues 
dos Passos, observer, at the Montreal  
Neurological Hospital.
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Fellowship in Morocco Productive for Mali Neurologist 
BY DR. BOUBACAR MAIGA
I would like to thank the WFN for giving me the opportunity to have a fellowship in clinical neurophysiology 
at the University Mohamed-V in Rabat 
in Morocco. I would like to express my 
sincere gratitude to Prof. Mustapha 
El Alaoui Faris, the coordinator of the 
Rabat Center, for his advice and follow-
up during my successful training. I also 
thank Prof. Reda Ouazzani, the head of 
the Department of Clinical Neurophysi-
ology, for his warm welcome and nice 
teaching. I also thank the department 
team: Profs. Nazha Birouk, Halima 
Belaidi, and Leila Errguig, and Drs. 
Fatiha Lahjouji and Bouchra Kabli. 
My training took place every week, 
from 9 a.m. to 3 p.m., Monday through 
Friday. I performed all of the neuro-
physiological explorations under the 
supervision of Prof. Ouazzani. In the 
department, I had the same activities as 
the Moroccan residents in neurology and 
neurophysiology. 
• Video EEG: I participated in the 
recording, reading, and interpreta-
tion of video EEGs for patients with 
epilepsy. I interpreted the EEGs alone 
at first, and then I discussed the EEG 
patterns with one of the professors in 
the department.
• EMG: Initially, I practiced EMG under 
the supervision of the professors. Then, 
I practiced EMG alone and discussed 
the protocol and patterns with one of 
the professors in the department. 
• Evoked potential exploration: I did time-
to-time evoked potentials with Dr. Kably.
• Neuromuscular outpatient visits: I regu-
larly attended the outpatient consulta-
tions on neuromuscular diseases with 
Prof. Birouk. 
• Epileptology: I attended the epilep-
tology consultations with Profs. Ouaz-
zani and Belaidi.  
The first six months were focused on 
EEG and epilepsy, and the focus in the 
last six months was on EMG and neuro-
muscular diseases.
Scientific Activities
I attended the departmental conference 
from 2:30 to 4 p.m. on Thursdays. There, 
we discussed interesting EMG and EEG 
cases selected from Monday through 
Wednesday. The last Friday of every 
the month, we held a multidisciplinary 
conference in the morning involving 
all of the neurology departments of the 
hospital. An oral presentation was made 
by each department, and the presenta-
tion was debated. In the afternoon, we 
had a multidisciplinary conference that 
included neurologists, neurosurgeons, 
and neuroradiologists at the National 
Center of Neurosciences and Rehabili-
tation inside the hospital Hôpital des 
spécialités. 
Congresses and Meetings
With the support of the Moroccan Soci-
ety of Neurology, I had the opportunity 
to attend the following meetings and 
congresses:
• May 5-7, 2016: The National Congress 
of the Moroccan Society of Neurology 
in Marrakesh 
• May 19-21, 2016: The Maghreb 
Congress of Neurology in Alger 
• Oct. 13-15, 2016: The course on Move-
ment Disorders, organized by the 
Movement Disorders Society and the 
Moroccan Association of Movement 
Disorders in Marrakesh. 
• Nov. 10-12, 2016: The Autumn 
Congress of the Moroccan Society of 
Neurology in Rabat. At the conference, 
I received an award for the best poster 
communication. 
• March 15-18, 2017: I presented an 
oral communication, “Phrenic Nerve 
Conduction Study in Six Patients 
With Amyotrophic Lateral Sclerosis 
and Review of the Literature,” at the 
African Academy of Neurology Confer-
ence, in Hammamet, Tunisia.
• March 28-31, 2017: Les Journées de 
Neurologie de Langue Française, the 
annual French meeting of neurology, in 
Toulouse. 
• April 27, 2016: I attended a course 
of Prof. Fabrice Bartolomei from 
Marseille on epilepsy and sleep. 
• I attended two seminars for residents of 
anatomy and physiology of the nervous 
system, organized by Faculty of Medi-
cine of Rabat.
• March 10-11, 2017: I attended an EMG 
Practical Workshop on Traumatic 
Nerve Injuries, animated by Prof. 
Emmanuel Fournier of Paris and Prof. 
Nazha Birouk of Rabat, in Marrakech.
To enhance my knowledge on 
the theoretical level, I enrolled in the 
University Diploma on EMG and on 
EEG.
I am satisfied with my fellowship in 
the Department of Neurophysiology 
at Rabat. Thank you for the scientific 
environment and the availability of the 
whole team of the department. I had an 
excellent stay in Rabat, during which 
I gained knowledge in both EEG and 
epileptology, as well as in EMG and in 
neuromuscular diseases.
I believe I will be able to pass on the 
knowledge in neurophysiology that I 
acquired in Rabat to my colleagues in 
Mali and help improve the practice of 
neurophysiology in my country. 
I am planning to use EEG and EMG 
at the teaching hospital of Point G to 
support the clinical evaluation needs 
of patients with epilepsy. I will do an 
EEG evaluation of study participants 
in a research project on autism in Mali. 
I am currently designing a study on 
EEG biomarker identification in autistic 
children. •
M O R O C C O  D E P A R T M E N T  V I S I T  P R O G R A M
PATHOLOGIES FREQUENTLY 
ENCOUNTERED
Video EEG
• Drug-resistant epilepsy
• Psychogenic non-epileptic  
seizures
 EMG
• Carpal tunnel syndrome
• Myopathies
• Motor neuron diseases
• Polyneuropathies
• Neuromuscular junction  
disorders
• Radiculopathies
Photo of the staff of the Department of Neurophysiology of Mohamed-V University of Rabat Sitting (from left): Prof. Halima Belaidi, Dr. Fatiha 
Lahjouji, and Prof. Nazha Birouk. Standing (from left): Dr. Bouchra Kably, and Profs. Alassane Dravé, Youannes Debebe, Boubacar Maiga, Fatima 
Hassane Djibo, Reda Ouazzani, and Leila Errguig.
“I believe I will be able to pass on the 
knowledge in neurophysiology that I 
acquired in Rabat to my colleagues in 
Mali and help improve the practice of 
neurophysiology in my country.”
Dr. Boubacar Maiga
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see AUSTRALIA, page 12
The Emergence of Clinical Neurology in Australia
A review of the work of five key authors who paved the way for the specialty in the Commonwealth.
BY M. J. EADIE
I n Northern Hemisphere countries, from about 1860 onward, the specialty of  clinical neurology emerged after 
increasing numbers of  medical graduates 
focused their interests and restricted their 
clinical practices to the study and manage-
ment of  organic disease of  the nervous 
system. A similar process occurred in 
Australia, but lagged by some four decades 
so that the specialty 
of  clinical neurology 
there became firmly 
established only by 
the mid-20th century. 
Several factors 
contributed to the 
Australian delay. 
European migration 
to the country began 
in 1788. Initially, the 
migration was composed largely of  convict 
settlements, with free settlers beginning 
to arrive a few decades later. The Austra-
lian population sites that developed were 
far from Northern Hemisphere cities and 
educational institutions and also were 
considerable distances from each other. 
The individual sites needed to become 
large enough before specialist medical 
practice was feasible in them. 
In the latter third of  the 19th century, 
accounts of  neurological disorders peculiar 
to Australia began to emerge. For example, 
children were being diagnosed with lead 
poisoning, and those who ate finger cherry 
fruit experienced acute bilateral visual 
failure. There were reports of  disorders, 
such as leprosy, beriberi neuritis, and tick 
bite paralysis, not often seen in temperate 
climates. With few exceptions, Australian 
authors did not publish again on the same 
topic. 
However, in the 1880s in Melbourne, 
John William Springthorpe became 
interested in epilepsy, and in the 1890s, 
S. Jamieson wrote on both syphilis and 
peripheral neuritis. 
George Edward Rennie
The first man to take a major continuing 
interest in clinical neurology in Australia 
was George Edward Rennie (1861-1923). 
Originally from Sydney, he received his 
medical education (MB and MD) at the 
University College London and returned 
to Sydney. By 1898, Dr. Rennie became an 
honorary physician to the Royal Prince 
Alfred Hospital. He resigned that appoint-
ment and returned to London. He took 
the membership of  the Royal College of  
Physicians, returned to Sydney in 1900, and 
re-ascended the honorary consultant ladder 
at his hospital to become its senior physi-
cian (from 1912 to 1921). 
Dr. Rennie seems not to have carried 
out any significant original research, but 
wrote on neurological topics, such as the 
functional anatomy of  the cerebellum, 
meralgia paraesthetica, the physiology 
of  voluntary movement, the curability of  
epilepsy, the treatment of  peripheral nerve 
diseases, the effects of  spinal cord transec-
tion, and the possibility that occupation 
and peripheral trauma might determine 
the site of  syphilitic cerebral pathology. 
He provided the neurological input to the 
main teaching hospital of  Australia’s largest 
city but, with writings on topics such 
as pneumonia, tuberculosis, pernicious 
anemia, childhood deafness, and endocrine 
topics, he never restricted his activities to 
clinical neurology.
Alfred Walter Campbell
Alfred Walter Campbell (1868-1937) was 
the first person in Australia to practice 
purely as a clinical neurologist. He was 
born on a pastoral property in southern 
New South Wales, educated locally, and, 
at the age of  18, traveled to Edinburgh, 
Scotland, for medical studies. He graduated 
with an MB CM in 1889. 
After short-term appointments in 
British psychiatric institutions and some 
months in Vienna with Richard von 
Krafft-Ebing, he spent a year at the State 
Asylum in Prague, where his histological 
research on “alcoholic neuritis” brought 
him an Edinburgh MD degree in 1892. He 
then became medical officer and resident 
pathologist at the Lancaster County 
Asylum (Rainhill), near Liverpool, where 
he spent the next 13 years publishing a 
considerable amount of  neuropatho-
logical investigation into various topics, 
such as the degeneration of  spinal tracts 
connected to the cerebellum. He was the 
sole author of  all of  this work, except 
for a lengthy account of  the pathology 
of  herpes zoster, co-authored with (the 
subsequently Sir) Henry Head. Head 
supplied the clinical data to correlate with 
Dr. Campbell’s histological findings in the 
nervous systems of  21 zoster sufferers. 
A map of  the distribution of  the human 
dermatomes resulted. Dr. Head’s role 
in this great achievement is still remem-
bered, while Dr. Campbell’s is forgotten.
From about 1900 on, Dr. Campbell 
systematically investigated the histology 
of  the entire normal human cerebral 
cortex, as a preliminary to searching 
for histological changes in the cortex 
that might correlate with mental illness, 
something that macroscopic pathology 
had failed to do. He studied serial sections 
from tissue blocks from 50 to 60 gyri per 
hemisphere in five hemispheres, staining 
alternate sections for myelinated nerve 
fibers and neuronal cell bodies, and in a 
further three hemispheres for nerve fibers 
only. He also sought retrograde cortical 
histological changes where altered brain 
function resulted from lesions below the 
cortex. He identified 12 histologically 
distinct areas in the cerebral cortex. 
The future Nobel Laureate C.S. Sher-
rington, then professor of  physiology in 
nearby Liverpool, read the findings on Dr. 
Campbell’s behalf  to the Royal Society 
of  London (1903 and 1904). The abstracts 
appeared in the society’s Philosophical 
Transactions, but the full paper was too 
extensive for publication. The society 
regarded the work highly enough to 
subsidize its publication by Cambridge 
University Press as Histological Studies on 
the Localization of  Cerebral Function. The 
monograph appeared in late 1905, some 
three years before Korbinian Brod-
mann’s similar 
investigation was 
published.
Before his 
monograph was in 
print, Dr. Camp-
bell returned to 
Australia, never 
leaving his homeland 
again except to serve 
with the Australian 
Army Medical Corps 
in Egypt during World 
War I. One factor in his 
abandoning his British 
career at his moment of  
triumph probably was his 1906 marriage 
in Sydney to a woman he had known since 
his rural childhood.
In Sydney, neuropathology was largely 
closed off  to him by Froude Flashman 
and Oliver Latham in the State Asylum 
Service, while Dr. Rennie did much of  the 
clinical neurology. Dr. Campbell began 
consultant practice in a mix of  neurology 
and neuropsychiatry, with the latter 
progressively fading from his activities. He 
held honorary consultant positions at the 
Sydney Children’s and Coast Hospitals, 
and after World War I, to the Repatriation 
Department. He continued some neuro-
pathological work, studying a gorilla brain 
given to him by Dr. Sherrington, and 
investigating in conjunction with Cleland 
the pathology and pathogenesis of  a viral 
encephalitis termed Australian X disease, 
now believed to have been Murray Valley 
encephalitis. He also sought histological 
evidence consistent with localization of  
function in the human and Australian 
animal cerebellar cortex. He published 
those findings in so obscure a site that 
they went almost entirely unnoticed. 
His other papers in Australia were 
more clinical. In 1937, he became ill 
with a malignancy, dying late in that 
year. He left behind no local school of  
clinical neurology. Sydney medicine, long 
reluctant to accept specialization within 
internal medicine, was not ready for it. Dr. 
Campbell’s reserved personality probably 
worked against him, and his earlier scien-
tific attainments were little appreciated in 
his homeland.
J. Froude Flashman
J. Froude Flashman (1870-1917) followed 
a career course similar to Dr. Campbell’s. 
In 1910, he moved from neuropa-
thology into consultant neurological and 
pathological practice in Sydney, largely 
to provide for his family. His original 
contributions to neuropathology, though 
appreciable, were not of  the magnitude 
of  Dr. Campbell’s. Dr. Flashman died of  
pneumonia while serving in the Australian 
Army Medical Corps in 1917 in France, 
soon after taking the MRCP qualification. 
Unfortunately, he did not have time to 
influence the development of  Australian 
clinical neurology. 
Leonard Bell Cox
A young Melbourne medical gradu-
ate, Leonard Bell Cox (1894-1976) took 
the Edinburgh MRCP qualification (in 
hematology) before returning home after 
front-line service in France during World 
War I. In Melbourne, he first held appoint-
ments in pathology while building up 
practice as a physician. From 1925 onward, 
he increasingly devoted himself  to clinical 
neurology, holding a formal appointment 
as a neurologist to the Alfred Hospital in 
that city. Among other investigations, he 
published some significant neuropatho-
logical research, including a major and 
influential study, “The Cytology of  the 
Glioma Group With Special Reference 
to Inclusion of  Cells Derived From the 
Invaded Tissue,” that appeared in the 
American Journal of  Pathology (1933), and 
a co-authored monograph (with Jean 
Tolhurst) on Human Torulosis. 
Edward Graeme Robertson
With the advent of  Dr. Cox, leadership 
in the development of  Australian clinical 
neurology shifted from Sydney to the 
country’s second city, Melbourne. There, 
(Sir) Sydney Sewell (1880-1949) held 
hospital consultant neurological appoint-
 M. J. EADIE
Alfred Walter Campbell (left) and 
Leonard Bell Cox.
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From Jungle to Metropolis
The journey of one neurologist from Sri Lanka to Melbourne 
BY TISSA WIJERATNE, MD
B orn and raised in what I describe as “the jungle,” my life started in one of  the remotest parts of  Sri Lanka: 
a village called Kirioruwa-Bandarawela in 
the central mountainous area. Electricity, 
hot water, television, and telephone were 
all miles away from us at the time. 
I fondly recall days spent reading in 
the shade of  a tree in the rice fields that 
surrounded my family home — the place 
where sky and earth met, almost kissing 
each other daily. The mountains were 
covered with a layer of  lush tea bushes. 
Our home sat on the top of  one of  these 
mountains. 
As a young boy, I would spend hours 
reading my favorite magazine, the Mihira, 
a children’s weekly.
Fast forward several decades. I am now 
the director of  stroke services, neurosci-
ence research unit, director of  academic 
affairs, and director of  international 
affairs at a leading public health service 
and a leading academic institution in 
Melbourne, Australia. I have just been 
appointed to chair of  the Department of  
Neurology at Western Health in Australia 
to promote better brain health through 
my leadership. 
I have become the first Sri Lankan-
born neurologist to lead an academic 
department of  neurology in Australia.
The Journey
I was always dreaming, ravenously read-
ing, thinking … trying to discover new 
things that others hadn’t, with a view to 
make life better for my fellow men and 
women.
I fell in love with the idea of  medi-
cine when I realized that the potential 
to change human life for the better was 
immeasurable.
I was accepted in to medical school at 
the University of  Peradeniya in 1987 as 
a merit student. This was purely an acci-
dent. I had no idea that I could end up in 
medical school while I truly loved biology 
as a high school student. I preferred to 
do the biology track as I truly enjoyed 
learning about biology and chemistry. In 
the end, I did well and secured a ticket to 
get in to the medical school. 
The day before I departed for the 
university, the whole village visited my 
parents with whatever treasure they could 
carry. 
“We are very proud of  you, son. Be a 
good doctor, and come back to the village. 
We will need you one day,” they said. 
I still recall my father’s deep voice 
while he was walking me to the railway 
station to get to the University premises 
from Bandarawela. 
“I am very proud of  you. I have no 
doubt you will go all the way. It is very 
important for you to remember your 
roots,” he said. “Whatever you become, 
every time you come home, you are one 
of  us, one of  them.” (He pointed to a 
fellow villager who was working along a 
farm yard.) “You should always be very 
humble,” he said.
University life was a dream come true 
for me. There was no rice field to work; 
no need to offer physical labor on the 
farm. It was a heaven made for learning. I 
easily picked up high marks at the univer-
sity exams. 
I recall coming back to the village and 
sharing my experience with other boys 
and girls. The gates were open for them to 
enter universities away from the village. 
Most of  the boys and girls worked hard 
to get to the university.
Uprising
The good times did not last long. Things 
changed for the worse in a few months.
Suddenly, it was a tough time in Sri 
Lanka. I did not see this coming. It was 
depressing. Part-way through my first year 
of  medical school life, a national youth 
uprising in 1987 resulted in several years 
of  chaos in the country, with educational 
establishments closed for the period of  
insurgency.
Many of  my batch mates were killed. 
They were suspected to have links with 
the youth-uprising group.
During what became a three-year 
hiatus, I tried to come to terms with the 
fact that I was not going to become a 
physician. I took solace in reading as much 
as I could, while helping my parents farm 
the surrounding rice fields and gardens in 
my rural village.
I really missed the university life. I 
missed the library the most. So, I began to 
convert my thoughts into words. I started 
to write.
I wrote poems and stories. In the 
end, many leading national newspapers 
and magazines in Sri Lanka published 
them one by one. In the end, I became 
well known in Sri Lanka, with over 3,000 
written pieces. I would sit under a tree 
in the rice fields and write. My thoughts 
at that time were that if  I could not be 
a physician, maybe I would become a 
journalist.
In 1990, the youth uprising was 
crushed, and the universities reopened. I 
faced a fork in the road. Should I continue 
with the new path and take up the post 
as deputy editor for a leading national 
science weekly in Sri Lanka, or return to 
my much-loved medical school and finish 
what I had started?
Ultimately, I chose medicine. I 
continued to work with media on a 
part-time basis, a decision that enabled 
me to pursue my tertiary studies without 
financially burdening my family. In my 
third year at the University of  Peradeniya 
Medical School, I decided that the brain 
was the most fascinating organ in the 
whole body.
The Mind
The human mind always fascinated me. 
In fact, I was often found in the canteen, 
unofficially tutoring many of  fellow 
medical students from my own class, as 
well as the juniors, on brain anatomy and 
neurological pathways. I was popular for 
demystifying neurosciences as a student at 
that time. I was quite interested in depres-
sion, anxiety, memory, and wisdom, and 
I often spoke on these topics on national 
radio at the time.
I had been learning about my own 
mind since I was a child, perhaps since 
I was about 10 or 11 years of  age. A lot 
of  people do not know their own minds. 
Most of  us either live in the past or 
future, not the present, and we become 
daydreamers. We forget what we need to 
do now. We forget to live in the moment. 
We ruminate in the past or future. This is 
the root cause for suffering among us.
I graduated with high marks and 
secured one of  the most prestigious 
internship appointments in Sri Lanka, at 
the professorial University Medical Unit 
and University Surgical Unit at National 
Hospital in Colombo, Sri Lanka.
Then fate intervened. I met a girl, 
who later became my wife. Born in Sri 
Lanka, she had moved to Australia as a 
young student in medicine and, as a fellow 
medical graduate, was taking an elective at 
a Sri Lankan hospital when she and I met.
At the completion of  my internship, I 
was handpicked to be the youngest junior 
lecturer at the University of  Peradeniya, 
being trained in neurology and stroke 
medicine under the mentorship of  Prof. 
Nimal Senayanake. This was a highly 
competitive position. Prof. Senayanake is 
well known to the World Federation of  
Neurology thanks to his significant contri-
butions in neurotoxicology in the past. 
Family
At the time, I was observing the brain drain 
happening around me as my peers left for 
the U.K., Australia, and America. I hated 
them. I strongly felt that they had a duty 
to serve in the less green parts of  the world.
Because of  my marriage, I had to leave 
Sri Lanka in the end. The guilt I felt at 
leaving my beloved homeland in 1998 cut 
deep. It was some months before I could 
make progress in establishing a new life in 
Australia with my wife. 
In 1999, my wife and I moved to 
New Zealand as part of  her training in 
psychiatry. I then had the good fortune of  
working with a remarkable young infec-
tious diseases physician, Dr. Richard Everts, 
who pushed me to complete physician 
training in Australasia while I was contem-
plating a neurobiology PhD at the time.
For the first time in my life, I could 
practice what I read in textbooks. I 
couldn’t do that in Sri Lanka.
After completing my basic physician 
training in New Zealand and having our 
first child in North Island, we moved 
south, to Christchurch, where I under-
took my advanced training in neurology 
with Prof. Tim Anderson and colleagues. 
Here, I developed my skills in movement 
disorders, stroke medicine, and headache 
medicine. I was on call for the EPITHET 
trial as an investigator 24/7 for nearly 
three years.
We then moved back to Australia, and 
I took up a post at the Royal Adelaide 
Hospital, where our second child was born. 
I underwent further training in stroke and 
movement disorders under the leadership 
of  Prof. Philip Thompson, then president 
of  the Movement Disorders Society.
In 2006, Prof. Robert Helme 
invited me to set up a stroke program, 
see METROPOLIS, page 12
Tissa Wijeratne, MD (right), with one of his mentors from his time as a student in Sri Lanka.
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ments from a little before World War I, 
but afterward shifted his interest into the 
area of  tuberculosis. Before doing that, he 
had encouraged Edward Graeme Robert-
son (1903-1975) to train in neurology in 
London where, after some distinguished 
clinical research work, he had already 
been appointed to a consultant post in 
neurology before returning to the Royal 
Melbourne Hospital in the mid-1930s. By 
that time, there also were physicians with 
major neurological interests, virtually de 
facto neurologists, in most of  the Austra-
lian state capital cities, and the speciality 
of  clinical neurology had arrived at its 
stage of  self-sustaining expansion. •
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neuroscience research program, and 
movement disorders program at Western 
Health, where resources were limited.
I went on to develop the fastest-
growing stroke service in Australia at 
Western Health. A number of  PhD 
students completed their higher degrees 
through the Western Health neuroscience 
research program. Our collaborations 
generated 10 to 15 high-quality publi-
cations in high-impact factor journals 
annually.
Prof. Helme is a remarkable person. 
We owe him a lot. He inspired a depart-
ment, helped me establish a research 
program at Western Health, and encour-
aged my interest in stroke medicine. He is 
still my mentor. We meet every six weeks 
or so over a coffee, and even though 
he criticizes me for not doing more, he 
always smiles at my achievements. 
I go back to Sri Lanka with surprising 
frequency, to promote better brain health 
in Sri Lanka. I have conducted more than 
150 master classes in stroke medicine, 
headache medicine, and movement disor-
ders throughout Sri Lanka since 2007. I 
have trained a young neurologist/physi-
cian from Sri Lanka at Western Health 
almost every year since 2008. At present, 
another Sri Lankan neurologist from 
Kandy is training with me in Melbourne, 
Australia. 
I spend almost 70 percent of  my 
annual leave returning to Sri Lanka. To 
my knowledge, I am the only permanent 
visiting professor of  neurology to be offi-
cially appointed to a Sri Lankan University.
Australia has one of  the best health 
care systems in the world, and I am proud 
to be a part of  it. We deliver state-of-the-
art care for our patients regardless of  how 
much is in their pocket.
I don’t believe in complaining or 
whining about what we don’t have. Not 
so long ago, I did not have any office 
space or a personal assistant at Western 
Health while I was leading one the 
biggest stroke services in Australia. I 
was using a dustbin along the corridor to 
lean on and sign paperwork. The stroke 
service head from Colombo National 
Hospital and two other physicians who 
visited me noticed this in 2009. Just 
because I am in Melbourne does not 
mean I have a silver spoon.
I believe I am a link between the devel-
oping world and the developed world. If  
someone turned back the clock to 1998, 
and I was given the option of  staying in Sri 
Lanka or coming to Australia, I would still 
come. I always wanted to do something 
great for the world and fellow human 
beings, and the Australian health system 
has given me the opportunities I never 
would have had in Sri Lanka.
Last year, I was very sick. I almost lost 
my life. At one point, I was told that I was 
not going to live more than two months. 
I recall the sleepless nights I had earlier in 
the illness.
“Did I get it wrong? I could have done 
more private practice and paid off  the 
mortgage. Why did I spend time traveling 
back and forth to Sri Lanka rather than 
building my wealth and CV?”
I knew the answer right away. This 
is the best way to live my life. There is 
nothing that makes us happier than giving 
and expecting nothing in return.
I enjoy perfect health at the moment. 
I will continue to do my very best to 
dedicate my life to making life better for 
my fellow human beings. I have no bound-
aries for this purpose. 
There is much more to do in this 
world. There is much more to do in the 
Asia-Pacific region. The World Federation 
of  Neurology is our platform to do this 
work and to get the job done.
Make sure you sign up for the advo-
cacy workshop at the upcoming world 
congress in Kyoto.
I look forward to seeing you all in 
Kyoto. Let’s get together and promote 
better brain health.
Let us bring our very best to get the 
best possible care for our patients, irre-
spective of  the resources we have. •
AFAN-PAUNS Congress 
Two societies achieve a milestone of joint regional meetings
BY RIADH GOUIDER, MD, AND  
WOLFGANG GRISOLD, MD
T he first African Academy of  Neurology (AFAN) conference and the 15th Pan Arab Union of  Neurolog-
ical Societies (PAUNS) meeting provided 
a unique opportunity for both societies 
to meet on the same premises and hold 
their first joint congress. More than 500 
delegates attended; they represented 52 
nationalities from five continents.
The Tunisian Society of Neurology, 
on behalf  of  the African Academy of 
Neurology and the Pan Arab Union 
of Neurological Societies, organized 
the meeting. To help young participants 
attend, the WFN, the American Academy 
of  Neurology (AAN) and the European 
Academy of  Neurology (EAN) initiated 
a joint sponsorship. The Tunisian Society 
of  Neurology was helpful and generous 
in supporting this event.
The congress took place in Yasmine-
Hammamet, Tunisia. The staff  of  
the Neurology Department of  Tunis 
served as host and conference organizer. 
Helping to make the conference a success 
was that it coincided with the Tunisian 
National Day of  Traditional Dress.
Important topics were presented each 
day of  the meeting:
• Day 1: Neurology training initiatives 
in Africa and infectious diseases of  the 
central nervous system
• Day 2: Epilepsy and movement disor-
ders
• Day 3: Inflammatory diseases and 
dementia
• Day 4: Stroke and neuro- 
pediatrics
The sessions were well attended and 
featured lively discussions. The opening 
session tackled inflammatory neuropa-
thies, coma, paraneoplastic syndromes, 
and recent advances in the understanding 
of  Parkinson’s disease. Many topics 
deserved attention, including inflam-
matory aspects of  the neuromuscular 
system, new investigation techniques, 
and new therapies. 
The meeting’s scientific program 
contained courses on epilepsy, stroke, 
and botulinum toxin use in dystonias. 
The program featured interesting 
e-poster presentations, which were well 
organized and showed promise that 
e-posters will be an important aspect of  
future meetings. The Tournament of  
the Mind winners were Dr. Osheik Seïdi, 
from Sudan, and Dr. Sywar Triki, from 
Tunisia.
The AFAN business meeting 
concluded with the selection of 
Prof. Fuad Abdallah, from Egypt, as 
president-elect, and Prof. Shamsideen 
Abayumi Ogun, from Nigeria, as 
president. The PAUNS business meeting 
also was held during the conference, 
with Prof. Chokri Mhiri, from Tunisia, 
elected president.
The WFN was represented by its 
president, vice president, general secre-
tary, and two elected trustees. The EAN 
president and an AAN representative also 
attended.
Conference organizers overcame 
many challenges. Besides organizing a 
large meeting, they brought together 
different societies and interests, and coor-
dinated the travel needs of  participants 
from low-income countries to make it 
affordable. •
METROPOLIS
continued from page 11
AUSTRALIA
continued from page 10
Delegates gathered for a photo at the conclusion of the first meeting of the African Academy of Neurology conference, in Yasmine-Hammamet, Tunisia.
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COPENHAGEN 
BY PROF. GUNHILD WALDEMAR AND  
JESPER ERDAL
W e are happy to present Copen-hagen as the possible host city  for the World Congress of  
Neurology 2021.
Denmark and Scandinavia
The Danish Neurological Society (DNS) 
was founded in 1900, and is probably 
the world’s oldest neurological society. 
Although mature of age, DNS is an active 
and lively society that in recent years has 
attracted a lot of dedicated young doctors.
Leading Danish neurologists have 
been active in international neurological 
societies for many years, including Prof. 
Jes Olesen, Prof. Per Soelberg Sørensen, 
and Prof. Gunhild Waldemar, who we 
propose for Congress president for WCN 
2021.
Greater Copenhagen is a world leader 
for research and development pending, 
clinical testing, and drug development. 
It comprises four life science universities 
with 50,000 students producing 2,000 
PhDs every year, more than 150 biotech 
and 200 medtech companies as well as 11 
university hospitals, leading researchers, 
clinicians, and academics.
The neurological communities in 
Scandinavia are closely linked and coop-
erate both clinically and academically. 
We are proud to have the full support of 
our friends and colleagues in the Swedish 
Neurological Association and the Norwe-
gian Neurological Association. 
Nordic Style
Copenhagen is a truly charming city with 
a distinct Nordic, cool style. It is famous 
for its many old buildings mixed with 
modern prize-winning architecture, new 
Nordic gastronomy, and green environ-
ment, with numerous bicycles. Copenha-
gen is a clean, safe city that has been voted 
the most livable city numerous times. 
Copenhagen has the main hub airport 
in northern Europe and an outstand-
ingly good infrastructure. It takes only 12 
minutes to travel from the airport to city 
center by the inexpensive metro. 
Bella Center
If  Copenhagen were to win the bid, WCN 
2021 would be held in October at Bella 
Center Copenhagen, Scandinavia’s leading 
and largest congress center. It is conve-
niently situated between the airport and the 
city center, only 10 minutes away from both 
downtown Copenhagen and the airport.
In recent years, Bella Center has been 
the venue of  several large international 
medical congresses.
Reaching Out to the Public
We will strive to make new knowledge 
from WCN 2021 known to the public and 
to the health care authorities by collabo-
rating closely with local and international 
media, patient organizations, and through 
various outreach activities.
The goal is to increase the public 
awareness of  the frequent and often 
disabling neurological diseases, and the 
many new possibilities for treatment, reha-
bilitation, and care. 
Academic-Industrial Cooperation
We wish to help create a congress in 
Copenhagen that promotes academic-
industrial dialogue. This is crucial because 
of  the obvious co-dependence. Along with 
the WFN, we will draw upon our interna-
tional industrial networks to build a solid 
collaboration, both before, during, and 
after the congress. With an uncompromis-
ing focus on high academic quality, we 
wish to attract industrial participants and 
to help include relevant industrial themes. 
Trainees, Young Neurologists, and 
Young Researchers
The congress in Copenhagen should serve 
as a hub for networking among young 
researchers, trainees, and young neu-
rologists. Our goal is to support and help 
develop the work of  the WFN Interna-
tional Working Group of  Young Neurolo-
gists and Trainees. In connection with the 
WCN in Copenhagen, we will give young 
neurologists the opportunity to visit Dan-
ish neurological departments and research 
groups. The Danish Association of  Young 
Neurologists will help take good care of  
our young foreign colleagues.
Our aim is creating friendship and 
international clinical and scientific 
networks that can last for years and 
develop further over time.
Support for Colleagues
It is important for our colleagues from 
low-income and low-middle income 
countries to have the opportunity to 
participate in the WCN 2021. Lundbeck 
Foundation has therefore offered to donate 
50 bursaries of  1,000 euros ($1,100 U.S.) 
each to neurologists from low-income and 
low-middle income countries. 
The Danish Neurological Society offers 
to donate half  of  the society’s profit from 
the congress to the World Federation of  
Neurology educational programs.
Welcome to Copenhagen in 2021
We sincerely hope to have the opportu-
nity to welcome you to Scandinavia and 
Copenhagen for the World Congress of  
Neurology 2021. We will do our utmost to 
ensure that the congress will be a success, 
and that each and every delegate will have 
an exceptional and unforgettable visit. •
Written on behalf of the Danish Neurological Society 
by Prof. Gunhild Waldemar and Jesper Erdal, presi-
dent of the Danish Neurological Society.
Copenhagen, a candidate host city for WCN 2021, is known as a charming, clean, safe, green 
city, with numerous bicycles.
Four European cities are bidding to host the World Congress of 
Neurology 2021, an international conference focused on advancing 
the diagnosis and treatment of neurological disorders. In this 
issue, World Neurology publishes four articles written by neurology 
organizations and professionals about why WCN 2021 should take 
place in Copenhagen, London, Marseille, or Rome.
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LONDON
M embers of  the Association of  British Neurologists (ABN) invite their colleagues throughout the 
world to join them in London to celebrate 
the 2021 World Congress of  Neurology.
We last hosted this event in London in 
2001, achieving a still unbroken record in 
delegate numbers. Much has happened in 
the intervening decades, both in London 
and in British neurology. 
• Excellent venue: Our proposed venue, 
London ExCeL, played its role as a 
sporting venue during the 2012 Olympics 
and has attracted a substantial number 
of  successful medical congresses, consis-
tently achieving higher delegate numbers 
than in previous or subsequent years. 
The Elizabeth Crossrail line, opening in 
2018, should further enhance the venue’s 
appeal, reducing travel time into central 
London to just 15 minutes.
• Neurology in the United Kingdom has 
grown significantly since 2001, from 
about 400 consultant neurologists in 
2001 to almost 800 in 2016. The ABN has 
more than 1,500 members, more than 
half  of  whom are consultant neurolo-
gists, with a growing and enthusiastic 
younger membership of  trainees, junior 
doctors, and medical students. 
• Successful meetings: Our 2016 annual 
conference, held in cooperation with the 
British Pediatric Neurology Association, 
attracted over 700 delegates supported 
by 100 abstract bursaries available to 
early career researchers. We hope to 
exceed that figure at our 85th anniver-
sary meeting in 2017. Our regular pre-
meeting training and development day, 
which includes sessions for foundation 
doctors, trainees, and general practitio-
ners, has grown in popularity each year. 
Its work was reinforced in 2016 by the 
introduction of  a Medical Students Day, 
which attracted over 100 delegates.
The association also held a joint 
symposium with the British Neuroscience 
Association in September 2016. It contrib-
utes symposia to its biennial Festival of  
Neuroscience and has commenced work 
with the Society of  British Neurological 
Surgeons on a joint meeting planned 
for autumn 2018. We are confident that 
a London-based World Congress of  
Neurology would be of  great interest to 
our colleagues in other neuroscience disci-
plines. Indeed, our bid is supported by 12 
of  our fellow U.K. and Irish neuroscience 
associations, and we offer these reasons 
we should host WCN 2021.
• Engaged and active membership: The 
ABN has more than 150 consultant and 
trainee members directly involved in 
council, research, training, services, 
standards, and subspecialty advisory 
committee roles. These comprise 
an excellent pool of  experience and 
enthusiasm from which to appoint our 
scientific program, teaching, social, and 
other congress committees.
• Committed to education: We are 
committed to developing neurological 
training at home and abroad. Current 
projects include abstract bursaries (for 
early career researchers attending ABN 
meetings), travel bursaries (facilitating 
educational and research visits to 
developing countries), clinical research 
training fellowships (supporting the 
next generation of researchers), under-
graduate prizes and intercalated degree 
bursaries (encouraging undergraduate 
interest in neurology). We provide 
speakers to many overseas meetings, 
and our international committee is 
charged with reviewing and extending 
this work.
• Superb travel connections: Our chosen 
venue, London ExCeL, is in the best-
connected city in the world that can be 
reached by more people, from more 
destinations, in less time, than any other 
global destination. WCN2021 will take 
place three years after the high-speed 
London Crossrail link opens, speeding 
conference attendees to the venue to 
hear the most cutting-edge neuroscience 
at a truly globally connected conference 
center. It will provide direct access  
from Heathrow Airport to ExCeL in  
43 minutes, with 12 trains per hour that 
can carry 1,500 passengers.
• U.K. is open: The ABN’s 2017 annual 
meeting theme in Liverpool is “A Port 
to a World.” This theme reflects our 
approach to neurology — welcoming 
colleagues from around the globe, 
treating patients from every land and 
every part of  society, and traveling over-
seas to learn and to share skills. Thus for 
us, WCN2021 in London will be an even 
bigger “port” to welcome the global 
neurological community.
• A notable anniversary: 2021 is a 
particularly appropriate year to invite 
the neurological world to London as it 
marks the 400th anniversary of  the birth 
of  Thomas Willis, considered by many 
as the father of  neurology. He was the 
first to coin the term “neurology” and 
to identify the Circle of  Willis anatomi-
cally. What better place for the WFN 
to celebrate this anniversary than in the 
country of  his birth?
We believe that a London-based World 
Congress of  Neurology would be both 
popular and scientifically successful, and 
we hope that we will be given the oppor-
tunity to welcome the congress to London 
in 2021.
Hashtag: #NeurologyIsOpen #London-
IsOpen Vote London #WFN2021 •
ABN conference delegates supporting the London WCN 2021 bid. Vote #NeurologyIsOpen 
#LondonIsOpen #WFN2021. 
Four European cities are bidding to host the World Congress of 
Neurology 2021, an international conference focused on advancing 
the diagnosis and treatment of neurological disorders. In this 
issue, World Neurology publishes four articles written by neurology 
organizations and professionals about why WCN 2021 should take 
place in Copenhagen, London, Marseille, or Rome.
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MARSEILLE
BY PROF. GILLES EDAN, PROF. JEAN-MARC 
LEGER AND PROF. JEAN-PHILIPPE AZULAY
F rance and the French Society of  Neurology would like to be a candi-date to host the World Congress 
of  Neurology in 2021. France has never 
had this opportunity before and would 
be proud to convince the Council of  
Delegates to choose our country. 
The Société de Neurologie de Paris 
was established on June 8, 1899, and its 
first meeting was held on July 6, 1899. 
It was renamed Société Française de 
Neurologie in 1949, and celebrated its 
100th birthday June 16, 1999, in Paris. Our 
society is one of  the oldest in the world, 
and a number of  famous neurologists are 
part of  our heritage. 
The French Society of  Neurology 
has an old and rich history, but also is a 
vivid society with an annual congress 
assembling more than 3,000 neurologists 
each year. The French teams are major 
contributors in all the fields of  clinical 
neurosciences and will work with the 
international committee to develop an 
amazing scientific program. It is also 
the decision of  the society to open the 
congress to participants from all around 
the world, with an intensive program of  
support dedicated to young neurologists. 
To emphasize and symbolize this 
opening to the world, the city that the 
French Society of  Neurology has chosen 
is Marseille. The oldest city of  France 
was founded in 600 BC and became the 
main Greek city of  the Western Mediter-
ranean. Marseille is the second-largest 
city in France and is located in the south 
of  the country by the Mediterranean 
Sea. It is the capital of  Provence, one of  
the most visited parts of  the world. 
The Phocean City is a cosmo-
politan port where people have met 
from around the world for centuries. 
Marseille is Europe’s door to all the 
Mediterranean countries, Africa, and 
Maghreb.
Marseille Provence Airport (MRS) 
welcomed 8.5 million passengers in 2016 
and is currently linked to 96 destina-
tions in 25 countries, with 129 scheduled 
services. MRS is well connected to all 
major hubs, providing easy access from 
all over the world at competitive airfares. 
Up to 36 daily flights are being offered to 
Paris-Charles de Gaulle ( just a 90-minute 
flight), London-Heathrow, Frankfurt, 
Munich, Amsterdam, Brussels, Madrid, 
Rome, Lisbon, Istanbul, Montreal, 
Algiers, Casablanca, and Tunis. It is only 
a 25-minute drive from the airport to 
Marseille city center. 
Marseille can be reached in less than 
three hours by high-speed train, with 
departures every hour. The train station is 
in the heart of  the city.
October is a perfect time to come and 
visit the Provence Cote-d’Azur region and 
make a stop in Paris. The average temper-
ature is 24°C/75°F, perfect weather to 
enjoy the Mediterranean Sea!
The entire French neurological 
community enthusiastically supports 
this candidacy and hopes that it will be 
successfully considered. •
Prof. Gilles Edan is the 2017 SFN president.  
Prof. Jean-Marc Leger is the WFN French delegate. 
Prof. Jean-Philippe Azulay is a member of the local 
organizing committee.
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Four European cities are bidding to host the World Congress of 
Neurology 2021, an international conference focused on advancing 
the diagnosis and treatment of neurological disorders. In this 
issue, World Neurology publishes four articles written by neurology 
organizations and professionals about why WCN 2021 should take 
place in Copenhagen, London, Marseille, or Rome.
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ROME
T he Italian Society of  Neurology (SIN) is bidding to host the 25th World Congress of  Neurology in 
2021 in Rome. The Society was founded 
in 1907 with the mission to promote the 
study of  neurology in Italy; foster scien-
tific research, education, and specialist 
updating; and improve the quality of  
care delivered to patients with neuro-
logical diseases. SIN is an association of  
public and private neurology specialists, 
working in community, hospital, and 
university settings. It represents 3,000 
members, making it the largest associa-
tion of  neurologists in Italy, providing a 
constantly growing number of  education 
and training activities.
The Society’s training and updating 
activities are designed to enhance care 
activities, promote research studies into 
nervous system diseases, and facilitate 
interaction with patient organizations. 
Much research work is recognized at the 
highest international levels, contributing 
to the prestige of the Italian neurological 
community. SIN develops and promotes 
a wealth of clinical and scientific 
initiatives. 
The vastness of  the spheres of  clinical 
neurology has prompted the develop-
ment of  working groups within SIN. 
Where required, these seek the expertise 
and contribution of  specialists from 
other disciplines with a view to providing 
exhaustive responses to population needs. 
SIN’s official journal, Neurological Sciences, 
has a 2016 impact factor close to 2 and is 
among the leading European scientific 
journals in the field.
Italy is a valid representative of  the 
European neurological community. The 
number of  practicing neurologists in Italy 
is among the highest on the continent and 
its research activities hold top-ranking 
positions in international indexes. 
Its geographic position and cultural 
vocation place Italy in a pivotal posi-
tion among nations with a longstanding 
neurological tradition and North African 
and Middle Eastern regions keenly 
committed to the field of  neurology. The 
Italian neurological community has many 
representative members in international 
societies in various branches of  neurology, 
besides supporting projects to develop 
care, research, and scientific updates in all 
neurological subspecialties.
An active and positive member of  the 
WFN, Italy has participated both at the 
structural level and in the WFN’s various 
ongoing activities. It should first be 
stressed that Rome was the venue of  the 
WFN World Congress in 1961, and many 
Italian clinical neuroscientists have played 
an active role in WFN activities over at 
least the last 50 years. 
Italy offers beautiful cities with 
modern conference venues, hotels, 
restaurants, infrastructure, and places of  
interest. Conference delegates coming to 
Italy will greatly enjoy the wide variety 
of  suitable venues that provide a high 
standard of  hospitality, with competitive 
prices compared to other European cities. 
No less important is that Italy, its history, 
and its culture attract high numbers of  
congress delegates. 
For a variety of  reasons, the presence 
of  many active neurologists from all  
over the world in Italy, be it temporarily or 
permanently, prompts the need to  
host WCN. 
Rome, often referred to as “The 
Eternal City,” is among the world’s most 
alluring venues, combining its leading role 
in the international multicultural scene 
with its millenary history. Alongside the 
splendors of  ancient Rome and impor-
tant archaeological remains, such as the 
Colosseum and the extensive Imperial 
Fora, visitors are party to some of  the best 
examples of  the world’s Renaissance art. 
Delegates will be able to admire the works 
of  some of  the greatest artists whose 
achievements continue to adorn the city 
as they have done over the centuries. The 
Italian capital is the home of  important 
museums (including the Vatican buildings) 
and interesting permanent exhibitions. A 
visit to this city will enhance the artistic 
passion of  enthusiasts of  every art form 
(painting, sculpture, music, etc.).
Last but not least, being the world 
capital of  Christianity, Catholic delegates 
from all over the world would have 
a wonderful opportunity to visit the 
Vatican.
Importantly, Rome can be easily 
reached from all corners of  the globe. In 
addition, a modern, functional, attractive 
convention center, designed by one of  the 
greatest living architects (Massimiliano 
Fuksas), has recently been opened in 
the city, rendering delegates’ time at the 
congress venue even more pleasant and 
productive. •
The legendary origins of Rome are seen in this sculpture of the wolf with the founders of  
Rome — Romulus and Remus.
Four European cities are bidding to host the World Congress of 
Neurology 2021, an international conference focused on advancing 
the diagnosis and treatment of neurological disorders. In this 
issue, World Neurology publishes four articles written by neurology 
organizations and professionals about why WCN 2021 should take 
place in Copenhagen, London, Marseille, or Rome.
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Submit An Abstract Today
Early Registration Deadline: June 15, 2017
Awards & Lectures
• Elsevier Young Investigators Award
• Soriano Award Lecture
• Fulton Award Lecture
• Masland Award Lecture
• Singhal Award Lecture
Program Highlights
• Over 30 Teaching Courses
• Tournament of the Minds
•  WFN Medals Presentation
and Presidential Symposium
• Regional Symposium
• Sponsored Symposium
